

Tryton Medical, Inc. Announces First Clinical Use Of Its Side-Branch Stent™ To Treat Coronary Bifurcation Lesions

BOSTON, May 12 -- Tryton Medical, Inc. announced today the first clinical use of its Tryton Side-Branch Stent (TM). The initial cases were performed at the Heart Center/Siegburg under the direction of Professor Eberhard Grube, M.D. "These cases demonstrate that a Tryton stent strategy provides a simple and easy way to treat complex bifurcation lesions with beautiful results," according to Professor Grube.

The Tryton First-In-Man Study is a multi-center clinical trial evaluating the utility of the Tryton Side-Branch Stent (TM) to treat coronary artery arterial lesions involving a bifurcation -- a blockage involving a major side-branch artery. The study is being performed at the Institute Cardiovascular Paris Sud, France (Marie-Claude Morice, Principal Investigator) and Heart Center/Siegburg, Germany (E. Grube, Principal Investigator).

Coronary artery disease located at the branch of arteries occurs in up to 25% of patients currently undergoing coronary stenting. "The designs of available drug eluting stents do not adequately address this group of patients," said Dr. Aaron Kaplan, Founder of Tryton and Associate Professor, Dartmouth Medical School. "Stents placed at bifurcations are currently associated with higher acute complications as well as late restenosis."

According to Tryton's Chief Technology Officer, Richard Davis, "The Tryton Side-Branch Stent (TM) is a unique balloon expandable, 5 French compatible system that is delivered with a single wire. When used in conjunction with any existing standard stent for the main vessel, it provides superior coverage and hoop strength to the origin of the side-branch."

About Tryton Medical, Inc.

Tryton was founded in 2003 by Aaron V. Kaplan, M.D. (Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Spray Venture Partners to develop proprietary stent technology to treat branchpoint lesions.

About Spray Venture Partners

Spray Venture Partners is a venture capital firm that has been focused exclusively on early stage medical technology companies since 1996. Spray has founded and invested in over 25 medical technology companies addressing major unmet clinical needs in fields including Cardiology, Orthopedics, Gynecology, Ophthalmology, Gastro/Intestinal, Urology, Pulmonology and Neurology.